Keyphrases
Type I Diabetes
100%
Type 1 Diabetes Mellitus (T1DM)
100%
Hypoglycemia Unawareness
100%
Dapagliflozin
100%
Short-term Use
100%
Hypoglycemia
42%
Placebo
28%
Glycated Hemoglobin
28%
Glucose Variability
28%
Randomized Double-blind
14%
Placebo-controlled
14%
Once-daily
14%
Disease Duration
14%
Hyperglycemic Clamp
14%
Treatment Duration
14%
Washout Period
14%
Controlled Crosses
14%
Continuous Glucose Monitor
14%
Hypoglycemia Risk
14%
Adjunctive Therapy
14%
Clinical Aspects
14%
Symptom Response
14%
Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i)
14%
Exogenous Glucose
14%
Glucose Clamp
14%
Hyperinsulinemic
14%
Medicine and Dentistry
Awareness
100%
Insulin Dependent Diabetes Mellitus
100%
Hypoglycemia
100%
Dapagliflozin
100%
Type 1 Diabetes
36%
Placebo
27%
Antidiabetic Agent
27%
Glycated Hemoglobin
18%
Disease Duration
9%
Clinical Feature
9%
Patient with Type 1 Diabetes
9%
Sodium Glucose Cotransporter 2 Inhibitor
9%
Continuous Glucose Monitor
9%
Pharmacology, Toxicology and Pharmaceutical Science
Insulin Dependent Diabetes Mellitus
100%
Hypoglycemia
100%
Dapagliflozin
100%
Placebo
27%
Antidiabetic Agent
27%
Glycosylated Hemoglobin
18%
Clinical Feature
9%
Disease Duration
9%
Sodium Glucose Cotransporter 2 Inhibitor
9%
INIS
glucose
100%
people
100%
patients
28%
hemoglobin
28%
diseases
14%
reduction
14%
risks
14%
symptoms
14%
sodium
14%
avoidance
14%
hypothesis
14%
men
14%
monitors
14%
washout
14%